People · Operator
Named in public records as an officer, director or promoter · active 2016–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Bioxytran, Inc | — | Biotechnology | Seed | $6.0M | $1.5M | 2019 |
| Oxygen Therapy, Inc. | — | Pharmaceuticals | Pre-Seed | $540K | $14.2M | 2016 |
| Alphageneron Pharmaceuticals, Inc. | — | Pharmaceuticals | Pre-Seed | $250K | $2.1M | 2023 |
Ola Soderquist at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ola Soderquist on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Platt | 2 | 4 |
| Dale H. Conaway | 2 | 3 |
| Henry J. Esber | 2 | 3 |
| Robert Brooks | 1 | 12 |
| Robert Clarke | 1 | 7 |
| Marc Lippman | 1 | 5 |
| Alan J. Hoberman | 1 | 1 |
| Yuval Kwintner | 1 | 1 |
| Bikash Verma | 1 | 1 |
| Graham Pockley | 1 | 1 |
| Anders N. Utter | 1 | 1 |
| Alan H Hoberman | 1 | 1 |
| Soderquist Ola | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.